Coya Raises $10M to Advance T-cell Therapy Now in Phase 2 ALS Trial

Coya Raises $10M to Advance T-cell Therapy Now in Phase 2 ALS Trial

285450

Coya Raises $10M to Advance T-cell Therapy Now in Phase 2 ALS Trial

Coya Therapeutics has raised $10 million in funding to advance the development of ALS001, a potential regulatory T-cell (Treg) therapy aiming to halt amyotrophic lateral sclerosis (ALS) progression, now in a Phase 2 study in patients. Proceeds raised in this series A funding round will also be used to introduce into testing similar treatments for other neurodegenerative disorders. “Patients with neurodegenerative diseases are in desperate need of transformative therapeutic options; harnessing the neuro-protective effects of Treg…

You must be logged in to read/download the full post.